A Randomized, Double-Blind, Placebo-Controlled, Phase 2b, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib) Ointment in Subjects With Pruritus Associated With Psoriasis Vulgaris

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib) Ointment in Subjects With Pruritus Associated With Psoriasis Vulgaris

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Pegcantratinib (Primary)
  • Indications Plaque psoriasis; Pruritus
  • Focus Therapeutic Use
  • Sponsors Sienna Biopharmaceuticals
  • Most Recent Events

    • 31 Oct 2017 New source identified and integrated (ClinicalTrials.gov; NCT03322137).
    • 24 Oct 2017 According to a Sienna Biopharmaceuticals media release, data expected in in the first half of 2019.
    • 24 Oct 2017 According to a Sienna Biopharmaceuticals media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top